Luiza Oliveira-Jorge

Luiza Oliveira-Jorge

Auto-generated profile, based on publicly available information

Luiza Oliveira-Jorge

Dept. Ciències Mèdiques Bàsiques, Facultat de Medicina, Universitat de Lleida, Av Rovira Roure 80, Lleida 25198, Spain; Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré (IRBLleida), Av. Alcalde Rovira Roure 80, Lleida 25198, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
FDFABIEN DELASPRE
FABIEN DELASPRE
MPMaria Pazos-Gil
Maria Pazos-Gil
LOLuiza Oliveira-Jorge
Luiza Oliveira-Jorge
ECElisa Cabiscol
Elisa Cabiscol
Friedreich ataxia (FA) is a neurodegenerative disease characterized by degeneration of the large sensory neurons and spinocerebellar tracts, muscle weakness, and hypertrophic cardiomyopathy. It is caused by a deficiency of the mitochondrial protein frataxin, leading to iron dyshomeostasis, defective energy production, and oxidative stress. Peroxisome proliferator-activated receptor gamma (PPARγ) and nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathways play crucial roles in regulating mitochondrial function and protecting against oxidative stress, and their dysregulation contributes to neuronal degeneration in FA. In this study, we used frataxin-deficient primary cultures of dorsal root ganglia neurons to better understand the mechanism of action of leriglitazone, a novel brain-penetrant, full, and selective PPARγ agonist, by assessing the rescue of several cellular markers altered under frataxin deficiency. Leriglitazone improved most of the analyzed parameters, including cell survival, mitochondrial respiratory activity, iron homeostasis, and oxidative stress. Moreover, increased lipid peroxidation, a key marker of ferroptosis, was almost completely rescued by leriglitazone. NRF2 and PPARγ coactivator 1 alpha (PGC1α) levels that were decreased in frataxin-deficient neurons were normalized by leriglitazone. Interestingly, the combination of leriglitazone and the NRF2 activator omaveloxolone, a drug that has been approved to treat FA, was able to rescue both survival and mitochondrial function. In summary, our findings in this neuronal model suggest that targeting the PPARγ pathway with leriglitazone may be a promising therapeutic strategy for FA by improving mitochondrial function, bioenergetic cell alterations, and iron homeostasis. Likewise, a combination therapy with omaveloxolone may be an alternative for FA patients.

23 January 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
ASArabela Sanz-Alcázar
Arabela Sanz-Alcázar
BSBegoña Sánchez-López
Begoña Sánchez-López
FDFABIEN DELASPRE
FABIEN DELASPRE
MPMaria Pazos-Gil
Maria Pazos-Gil
ECElisa Cabiscol
Elisa Cabiscol
Friedreich ataxia (FA) is a rare, multisystemic neurodegenerative disorder caused by a deficiency of the mitochondrial protein frataxin. It is characterized by degeneration of the large sensory neurons in the dorsal root ganglia (DRG) and spinocerebellar tracts, leading to progressive neurodegeneration and muscle weakness. Frataxin deficiency induces iron dyshomeostasis, defective energy production, and oxidative stress, all regulated by NRF2. Omaveloxolone, an NRF2 activator, is currently the only approved therapy for FA; however, its effects on DRG neurons remain unknown. Here we used frataxin-deficient DRG neurons to better understand the drug's role in these sensory neurons. Omaveloxolone improved most of the analyzed parameters, including frataxin levels, cell survival, mitochondrial respiratory activity, iron homeostasis, oxidative stress, transferrin receptor 1 and glutathione peroxidase 4 levels, as well as the GSH/GSSG ratio. Moreover, lipid peroxidation, a key marker of ferroptosis that was increased in frataxin-deficient neurons, was almost completely rescued by omaveloxolone. Both total and nuclear NRF2 levels were decreased in frataxin-deficient neurons, and omaveloxolone treatment fully prevented this alteration. In addition, most of these results were validated in fibroblasts from FA patients. We also evaluated a combinatorial treatment using low doses of omaveloxolone together with honokiol, a SIRT3 activator with known neuroprotective properties. This combination enhanced cell survival and produced a synergistic effect increasing mitochondrial respiration in frataxin-deficient DRG neurons. In summary, these findings demonstrate the beneficial effects of omaveloxolone and further suggest that combination therapy with honokiol may provide an effective strategy for the treatment of FA, potentially mitigating adverse effects.

6 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LOLuiza Oliveira-Jorge
Luiza Oliveira-Jorge
LCLaia Castells-Roca
Laia Castells-Roca
MPMaria Pazos-Gil
Maria Pazos-Gil
MPMarta Portillo-Carrasquer
Marta Portillo-Carrasquer
BSBegoña Sánchez-López
Begoña Sánchez-López
JTJordi Tamarit
Jordi Tamarit
Friedreich ataxia is a rare cardio-neurodegenerative disease caused by reduced frataxin expression, resulting in iron-sulfur deficiency, oxidative stress sensitivity and decreased mitochondrial function. Sequence and structural analyses identified four residues—two serines, a tyrosine, and a glutamate—conserved across eukaryotic frataxins and Rickettsia CyaY proteins. Baker–Hubbard algorithm predicted that these residues form a hydrogen-bond network linking frataxin's α2 helix and β-sheet. To investigate the role of these residues, we engineered Saccharomyces cerevisae for expressing variant forms of yeast frataxin (Yfh1) at physiological levels. Mutating serines or glutamate caused partial protein loss. Oxygen consumption rate, specific aconitase activity and H2O2 sensitivity of these strains strongly correlated with remaining Yfh1 levels, suggesting that the investigated residues are required for frataxin stability but not for these functions. However, they showed high cupper sensitivity, indicating that these residues contribute to cuproptosis resistance. Furthermore, we purified wild-type human frataxin and variants E189A, S158A, S161A, Y143I, and Y143I/E189A. Thermal denaturation assays revealed that the variants decreased frataxin melting temperature (Tm), with the E189A variant exhibiting the most marked effect. This observation is consistent with the Baker–Hubbard prediction, as E189 is the only residue within the alfa-helix and is therefore essential for the H-bond network. Finally, we assessed the protective capacity of frataxin against metal-catalysed oxidation, confirming that frataxin presents antioxidant and iron-binding properties. We can conclude that frataxin presents metal-binding an antioxidant capacity and that the conserved residues investigated increase frataxin thermal stability and resistance to cuproptosis.